Preview

Obstetrics, Gynecology and Reproduction

Advanced search

Advisory Board on potential import substitution of follitropin alfa preparations in IVF cycles

https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.246

Full Text:

Abstract

On July 17, 2021, Advisory Board with the participation of more than 60 leading reproductive specialists and healthcare executives was held. The primary task was to discuss the real world data on the first Russian biosimilar follitropin alfa and the possibilities of import substitution of follitropin alfa drugs. The information about drug development stages, experience of usage in ovarian stimulation for artificial insemination and assisted reproductive technologies (ART), the results of the largest Russian study in reproduction "FОLLITROPIN" (2020), where biosimilar recombinant human follicle stimulating hormone (FSH) was studied in 5484 IVF cycles in real clinical practice, experience of drug use in leading ART medical centers have been provided in research reports. After discussion the Advisory Board Resolution has been developed.

About the Author

article Editorial

Russian Federation


References

1. ART Register. 2018 Annual Report. [Registr VRT. Otchet za 2018 god]. RARCh, 2018. 80 p. (In Russ.). Available at: https://rahr.ru/registr_otchet.php. [Accessed: 08.10.2021].

2. Vorobiev I.I., Semikhin A.S., Golovina E.O. The novel biosimilar of follitropin alpha to be manufactured in Russia starting from 2017. [Proizvodstvo novogo bioanalogovogo follitropina al'fa v Rossii - eto uzhe real'nost' v 2017 godu]. Obstetrics, Gynecology and Reproduction. 2017;11(3):116-26. (In Russ.). https://doi.org/10.17749/2313-7347.2017.11.3.116-126.

3. Kamilova D.P., Ovchinnikova M.M., Ablyaeva E.Sh. et al. An observational study «FOLLITROPIN» comparing the efficacy of follitropin alpha biosimilar: the real-world data. [Effektivnost' primeneniya bioanalogovogo follitropina al'fa v real'noj klinicheskoj praktike: rezul'taty nablyudatel'nogo issledovaniya «FOLLITROPIN»]. Obstetrics, Gynecology and Reproduction. 2021;15(1):5-21. (In Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.212.

4. Niederberger C., Pellicer A., Cohen J. et al. Forty years of IVF. Fertil Steril. 2018;110(2):185-324.e5. https://doi.org/10.1016/j.fertnstert.2018.06.005.

5. Directive 2004/27/EC of the European Parliament and of the Council, Art. 10.1. 2004. 24 p. Available at: https://ec.europa.eu/health/sites/default/files/files/eudralex/vol-1/dir_2004_27/dir_2004_27_en.pdf.

6. Federal Law "On the Circulation of Medicines" dated 12.04.2010 No. 61-FZ. [Federal'nyj zakon «Ob obrashchenii lekarstvennyh sredstv» ot 12.04.2010 № 61-FZ]. (In Russ.). Available at: https://normativ.kontur.ru/document?moduleId=1&documentId=395983.

7. WHO Technical Report Series 937, annex 7 «Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability». WHO Expert Committee on Specifications for Pharmaceutical Preparations. WHO, 2006. 478 p. Available at: https://apps.who.int/iris/bitstream/handle/10665/43443/WHO_TRS_937_eng.pdf?sequence=1.

8. Genazzani A.A., Biggio G., Caputi A.P. et al. Biosimilar drugs: concerns and opportunities. BioDrugs. 2007;21(6):351-6. https://doi.org/10.2165/00063030-200721060-00003.

9. Orlova N.A., Kovnir S.V., Hodak J.A. et al. Improved elongation factor-1 alpha-based vectors for stable high-level expression of heterologous proteins in Chinese hamster ovary cells. BMC Biotechnol. 2014;14:56. https://doi.org/10.1186/1472-6750-14-56.

10. Orlova N., Kovnir S., Khodak Y. et al. High-level expression of biologically active human follicle stimulating hormone in the Chinese hamster ovary cell line by a pair of tricistronic and monocistronic vectors. PLoS One. 2019;14(7):e0219434. https://doi.org/10.1371/journal.pone.0219434.

11. State Register of Medicines of the Russian Federation. [Gosudarstvennyj reestr lekarstvennyh sredstv RF]. (In Russ.). Available at: http://grls.rosminzdrav.ru. [Accessed: 07.06.2021].

12. Butts S.F., Seifer D.B., Koelper N. et al. Vitamin D deficiency is associated with poor ovarian stimulation outcome in PCOS but not unexplained infertility. J Clin Endocrinol Metab. 2019;104(2):369-78. https://doi.org/10.1210/jc.2018-00750.

13. Goncharova E.V., Donnikov A.E., Kadochnikova V.V. et al. Real-time RT-PCR diagnostics of virus causing COVID-19. [Diagnostika virusa, vyzyvayushchego COVID-19, metodom PCR v real'nom vremeni]. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2020;13(1):52-63. (In Russ.). https://doi.org/10.17749/2070-4909.2020.13.1.52-63.

14. Budani M.C., Fensore S., Di Marzio M., Tiboni G.M. Efficacy and safety of follitropin alpha biosimilars compared to their reference product: a metaanalysis. Gynecol Endocrinol. 2021;37(5):406-14. https://doi.org/10.1080/09513590.2020.1792437.

15. FOLLITROPIN - "The use of a biosimilar recombinant human follicle stimulating hormone in cycles of extracorporeal fertilization - an observational study in a real clinical practice". [FOLLITROPIN -«Primenenie bioanalogovogo preparata rekombinantnogo chelovecheskogo FOLLikulostimuliruyushchego gormona v cIklah eksTRakorporal'nogo OPlodotvoreniya - nablyudatel'noe Issledovanie v usloviyah real'Noj klinicheskoj praktiki»]. (In Russ.). Research site: https://follitropin.ru. [Accessed: 08.08.2021].

16. An Observational Study of Follitropin Alpha Biosimilar: the Real-world Data. ClinicalTrials.gov Identifier: NCT04854707. Available at: https://clinicaltrials.gov/ct2/show/NCT04854707. [Accessed: 08.08.2021].

17. Barakhoeva Z.B., Vovk L.A., Zorina I.V. et al. Major results of a phase III comparative multicenter study on the follitropinalfa biosimilar (Primapur®) and the original follitropin alfa (Gonal-f®). [Osnovnye rezul'taty sravnitel'nogo mnogocentrovogo issledovaniya III fazy bioanalogovogo follitropina al'fa (Primapur®) i original'nogo follitropina al'fa (Gonal-f®)]. Obstetrics, Gynecology and Reproduction. 2018;12(3):5—16. (In Russ.). https://doi.org/10.17749/2313-7347.2018.12.3.005-016.

18. Barakhoeva Z., Vovk L., Fetisova Yu. et al. A multicenter, randomized, phase III study comparing the efficacy and safety of follitropin alpha biosimilar and the original follitropin alpha. Eur J Obstet Gynecol Reprod Biol. 2019;241:6-12. https://doi.org/10.1016/j.ejogrb.2019.07.032.

19. Study to Compare Efficacy and Safety of Primapur and Gonal-f in Women for Assisted Reproductive Treatment. ClinicalTrials.gov Identifier: NCT03088137/. Available at: https://clinicaltrials.gov/ct2/show/NCT03088137. [Accessed: 08.08.2021].

20. Vorob'ev I.I., Proskurina O.V., Khodak Yu.A. et al. Physicochemical properties, toxicity and specific activity of follitropin alfa biosimilar. [Fiziko-himicheskie svojstva, toksichnost' i specificheskaya aktivnost' bioanalogovogo follitropina al'fa]. Himiko-farmacevticheskij zhurnal. 2016;50(11):35-42. (In Russ).

21. Tyul'kina E.E., Gordeev I.G., Grebenkin D.Yu. et al. Randomized crossover comparative study of safety, tolerance and pharmacokinetics of Primapur® vs. Gonal-f® upon singledose subcutaneous administration in healthy volunteers. [Sravnitel'noe randomizirovannoe perekrestnoe issledovanie perenosimosti i farmakokinetiki preparatov Primapur® i Gonal-f® pri odnokratnom podkozhnom vvedenii zdorovym dobrovol'cam]. Eksperimental'naya i klinicheskaya farmakologiya. 2017;80(4):13-7. (In Russ). https://doi.org/10.30906/0869-2092-2017-80-4-13-17.

22. Kirsanova O.V., Omelyanovsky V.V. Options to optimize the access to biosimilars: analysis and solutions. [Analiz problemy regulirovaniya dostupa k biosimilyaram i puti resheniya]. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2018;11(1):50-5. (In Russ.). https://doi.org/10.17749/2070-4909.2018.11.1.050-055.


Review

For citation:


Advisory Board on potential import substitution of follitropin alfa preparations in IVF cycles. Obstetrics, Gynecology and Reproduction. 2021;15(4):470-492. (In Russ.) https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.246

Views: 227


ISSN 2313-7347 (Print)
ISSN 2500-3194 (Online)